Patents by Inventor Lauge Schäffer
Lauge Schäffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8722849Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 8, 2012Date of Patent: May 13, 2014Assignee: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140087995Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: NOVO NORDISK A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Publication number: 20140018286Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicant: NOVO NORDISK A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20140011732Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: June 28, 2013Publication date: January 9, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
-
Patent number: 8575090Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 8, 2012Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Patent number: 8575091Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 28, 2013Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Publication number: 20130281363Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 28, 2013Publication date: October 24, 2013Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Patent number: 8486890Abstract: The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.Type: GrantFiled: March 15, 2007Date of Patent: July 16, 2013Assignee: Novo Nordisk A/SInventors: Thomas Kruse Hansen, Lauge Schäffer, Jesper Lau
-
Publication number: 20130059770Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 8, 2012Publication date: March 7, 2013Applicant: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20130012427Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 8, 2012Publication date: January 10, 2013Applicant: NOVO NORDISK A/SInventors: LAUGE SCHAEFFER, THOMAS KRUSE, HENNING THOEGERSEN
-
Publication number: 20130005646Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 8, 2012Publication date: January 3, 2013Applicant: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20120283170Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.Type: ApplicationFiled: May 1, 2012Publication date: November 8, 2012Applicant: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
-
Publication number: 20110152183Abstract: Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety is attached to the hybrid peptide, optionally via a linker.Type: ApplicationFiled: June 25, 2009Publication date: June 23, 2011Applicant: Novo Nordisk A/SInventors: Lauge Schäffer, Thomas Kruse
-
Publication number: 20110105394Abstract: The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention.Type: ApplicationFiled: October 21, 2009Publication date: May 5, 2011Applicant: NOVO NORDISK A/SInventors: LAUGE SCHÄFFER, THOMAS KRUSE, JESPER LAU, HENNING THØGERSEN
-
Publication number: 20110082079Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: April 7, 2011Applicant: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Runge, Henning Thøgersen, Ingrid Petersson
-
Publication number: 20100292133Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: November 18, 2010Applicant: Novo Nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, János Tibor Kodra, Kjeld Madsen, Patrick William Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thøgersen, Igrid Pettersson
-
Publication number: 20100261637Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: September 5, 2008Publication date: October 14, 2010Applicant: Novo nordisk A/SInventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Søren Østergaard, Steffen Reedtz-Runge, Henning Thøgersen
-
Publication number: 20100222269Abstract: The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such.Type: ApplicationFiled: September 11, 2008Publication date: September 2, 2010Applicant: Novo Nordisk A/SInventors: Lauge Schäffer, Thomas Kruse, Jesper Lau
-
Publication number: 20090318353Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.Type: ApplicationFiled: August 24, 2007Publication date: December 24, 2009Applicant: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schäffer, Jane Spetzler
-
Patent number: 6875741Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.Type: GrantFiled: September 24, 2001Date of Patent: April 5, 2005Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen